"Zalcitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
| Descriptor ID |
D016047
|
| MeSH Number(s) |
D03.383.742.680.245.500.950 D13.570.230.329.950 D13.570.230.500.925 D13.570.685.245.500.950
|
| Concept/Terms |
Zalcitabine- Zalcitabine
- Dideoxycytidine
- 2',3'-Dideoxycytidine
- 2',3' Dideoxycytidine
- ddC (Antiviral)
|
Below are MeSH descriptors whose meaning is more general than "Zalcitabine".
Below are MeSH descriptors whose meaning is more specific than "Zalcitabine".
This graph shows the total number of publications written about "Zalcitabine" by people in this website by year, and whether "Zalcitabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Zalcitabine" by people in Profiles.
-
Levine AM, Tulpule A, Espina B, Boswell W, Buckley J, Rasheed S, Stain S, Parker J, Nathwani B, Gill PS. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Cancer. 1996 Aug 01; 78(3):517-26.
-
Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996 Feb; 173(2):355-64.
-
Nusbaum NJ, Abraham T. Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy. Anticancer Drugs. 1996 Jan; 7(1):109-14.